Get the Stockscreener App
19.95
1.68%
-0.34
Acadia Pharmaceuticals Inc stock is traded at $19.95, with a volume of 1.98M.
It is down -1.68% in the last 24 hours and up +11.51% over the past month.
Acadia Pharmaceuticals Inc is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecules drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
See More
Previous Close:
$20.29
Open:
$20.51
24h Volume:
1.98M
Relative Volume:
0.87
Market Cap:
$3.32B
Revenue:
$890.53M
Net Income/Loss:
$30.57M
P/E Ratio:
110.83
EPS:
0.18
Net Cash Flow:
$80.53M
1W Performance:
-0.45%
1M Performance:
+11.51%
6M Performance:
+25.24%
1Y Performance:
-19.78%
1-Day Range:
$19.92
$20.68
1-Week Range:
$19.52
$20.68
52-Week Range:
$14.15
$26.56
Acadia Pharmaceuticals Inc Stock (ACAD) Company Profile
Name
Acadia Pharmaceuticals Inc
Sector
Industry
Phone
858-558-2871
Address
12830 EL CAMINO REAL, SAN DIEGO
Compare ACAD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACAD
Acadia Pharmaceuticals Inc
|
19.95 | 3.32B | 890.53M | 30.57M | 80.53M | 0.18 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Acadia Pharmaceuticals Inc Stock (ACAD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-11-25 | Initiated | Deutsche Bank | Hold |
| Jan-03-25 | Downgrade | Guggenheim | Buy → Neutral |
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Aug-07-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-27-24 | Initiated | BMO Capital Markets | Outperform |
| Mar-12-24 | Downgrade | Mizuho | Buy → Neutral |
| Mar-12-24 | Reiterated | Needham | Buy |
| Jan-30-24 | Initiated | Robert W. Baird | Outperform |
| Jan-24-24 | Upgrade | Needham | Hold → Buy |
| Dec-19-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-14-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Dec-13-23 | Initiated | Citigroup | Buy |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Nov-06-23 | Upgrade | Mizuho | Neutral → Buy |
| Oct-17-23 | Initiated | UBS | Buy |
| Oct-10-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-03-23 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-04-22 | Downgrade | Goldman | Neutral → Sell |
| Nov-01-22 | Initiated | Loop Capital | Hold |
| Aug-08-22 | Downgrade | Citigroup | Buy → Neutral |
| Aug-05-22 | Downgrade | Citigroup | Buy → Neutral |
| Jun-21-22 | Downgrade | Jefferies | Buy → Underperform |
| Jun-16-22 | Upgrade | Jefferies | Hold → Buy |
| Mar-16-22 | Upgrade | Canaccord Genuity | Hold → Buy |
| Feb-09-22 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jan-05-22 | Upgrade | Citigroup | Neutral → Buy |
| Dec-21-21 | Downgrade | Guggenheim | Buy → Neutral |
| Nov-01-21 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-14-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-23-21 | Resumed | Needham | Hold |
| Jun-10-21 | Initiated | Berenberg | Hold |
| Apr-07-21 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Apr-06-21 | Downgrade | Canaccord Genuity | Buy → Hold |
| Apr-06-21 | Downgrade | Goldman | Buy → Neutral |
| Apr-06-21 | Downgrade | Jefferies | Buy → Hold |
| Apr-06-21 | Downgrade | Mizuho | Buy → Neutral |
| Apr-05-21 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Mar-10-21 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-09-21 | Downgrade | Citigroup | Buy → Neutral |
| Mar-09-21 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-09-21 | Reiterated | H.C. Wainwright | Buy |
| Mar-09-21 | Downgrade | Raymond James | Strong Buy → Outperform |
| Mar-09-21 | Downgrade | Stifel | Buy → Hold |
| Dec-16-20 | Initiated | Mizuho | Buy |
| Nov-16-20 | Upgrade | Raymond James | Outperform → Strong Buy |
| Aug-25-20 | Initiated | Raymond James | Outperform |
| Aug-20-20 | Initiated | Morgan Stanley | Overweight |
| Jul-07-20 | Upgrade | Stifel | Hold → Buy |
| Apr-16-20 | Initiated | Jefferies | Buy |
| Mar-31-20 | Upgrade | Goldman | Neutral → Buy |
| Mar-06-20 | Initiated | Citigroup | Buy |
| Dec-16-19 | Initiated | Guggenheim | Buy |
| Oct-24-19 | Initiated | Oppenheimer | Perform |
| Oct-01-19 | Initiated | RBC Capital Mkts | Outperform |
| Sep-13-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Sep-10-19 | Upgrade | Canaccord Genuity | Hold → Buy |
| Jul-23-19 | Reiterated | Needham | Buy |
| Dec-10-18 | Initiated | Canaccord Genuity | Hold |
| Sep-21-18 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Aug-09-18 | Reiterated | Stifel | Hold |
| Aug-07-18 | Initiated | Stifel | Hold |
| Aug-06-18 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Oct-06-17 | Resumed | Goldman | Neutral |
View All
Acadia Pharmaceuticals Inc Stock (ACAD) Latest News
Director Commercial Launch Excellence and PlanningAcadia Pharmaceuticals Inc. - Built In
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Shares Sold by Rice Hall James & Associates LLC - MarketBeat
ACADIA Pharmaceuticals (ACAD) to Release Quarterly Earnings on Tuesday - MarketBeat
Drug developers struggle in 2024; Fibrogen, Acadia, Atai post gains - BioWorld Online
JP Morgan Week 2025 – Catherine Owen Adams - pharmaphorum
ACADIA Pharmaceuticals Shows Rising Price Performance With Jump To 82 RS Rating - Investor's Business Daily
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Short Interest Down 5.2% in January - MarketBeat
Acadia Pharmaceuticals Turns Heads with Ambitious Stock Awards - mivalle.net.ar
Biotech Giant Acadia Pharmaceuticals Lures Talent with Slick New Stock Incentives - Jomfruland.net
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)February 14, 2025 - BioSpace
ACADIA Pharmaceuticals (NASDAQ:ACAD) Now Covered by Analysts at Deutsche Bank Aktiengesellschaft - MarketBeat
Is the Options Market Predicting a Spike in ACADIA Pharmaceuticals (ACAD) Stock? - MSN
Acadia Pharmaceuticals: Good Progress Means I'm Reversing My 'Sell' Call To 'Buy' - Seeking Alpha
Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025 - Business Wire
10 Health Care Stocks With Whale Alerts In Today's Session - Benzinga
Deutsche Bank Initiates Coverage of ACADIA Pharmaceuticals (ACAD) with Hold Recommendation - MSN
Acadia's Q4 Results Coming: Major Updates on Breakthrough Parkinson's and Rett Syndrome Treatments - StockTitan
Deutsche Bank sets Acadia Pharmaceuticals stock target at $22 By Investing.com - Investing.com Nigeria
Deutsche Bank sets Acadia Pharmaceuticals stock target at $22 - MSN
Deutsche Bank Initiates Coverage on ACADIA Pharmaceuticals With Hold Rating, $22 Price Target - Marketscreener.com
Neuroregeneration Therapy Market to Surpass USD 64.8 Billion by 2034, Driven by Advancements in Regenerative Medicine and Rising Neurological Disorders | Transparency Market Research - GlobeNewswire Inc.
BlackRock, Inc. Increases Stake in ACADIA Pharmaceuticals Inc. - GuruFocus.com
High Growth Tech Stocks To Watch In February 2025 - Simply Wall St
Schizophrenia Market Expected to rise, 2034 | Boehringer - openPR
Leerink Partnrs Brokers Increase Earnings Estimates for ACAD - MarketBeat
Leerink Partnrs Has Optimistic Outlook of ACAD Q4 Earnings - MarketBeat
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Short Interest Update - Defense World
Q4 EPS Estimate for ACADIA Pharmaceuticals Raised by Analyst - Defense World
DCGI nod to Bajaj Healthcare for manufacturing Parkinson's disease psychosis drug Pimavanserin in India - Medical Dialogues
ACADIA Pharmaceuticals' SWOT analysis: stock outlook amid mixed product performance - MSN
3 Hidden Bargains in the Healthcare Sector - Inkl
VTRS: 3 Hidden Bargains in the Healthcare Sector - StockNews.com
How Biopharma Leaders Are Leveling Up Sales Strategies For 2025 - FiercePharma
Acadia’s New CEO Outlines Growth Strategy - News & Insights
Brokerages Set ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Target Price at $25.25 - MarketBeat
Acadia (ACAD) Q4 Earnings Lag, Sales Beat Estimates, Stock Down - MSN
ACADIA Pharmaceuticals (NASDAQ:ACAD) Stock Price Up 6.4%Still a Buy? - MarketBeat
Research Analysts Offer Predictions for ACAD FY2025 Earnings - Defense World
Brokers Issue Forecasts for ACAD FY2025 Earnings - MarketBeat
SG Americas Securities LLC Increases Stake in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - MarketBeat
ACADIA Pharmaceuticals (ACAD) Stock Price, News & Analysis - MarketBeat
ACAD Seeks EU Nod for Rett Syndrome Drug, Outlines 2025 Pipeline Goals - MSN
ACADIA Pharmaceuticals (NASDAQ:ACAD) Stock Price Down 6.9%Time to Sell? - MarketBeat
JPM25: After taking the wheel at Acadia, CEO Catherine Owen Adams looks to steer firm toward $1B in sales - FiercePharma
Acadia Pharmaceuticals Inc Stock (ACAD) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.27%
3.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):